Dishman Carbogen Amcis Quarterly Results
Dishman Carbogen Amcis quarterly results. In Sept 2026, Dishman Carbogen Amcis (DCAL) reported revenue ₹511 Cr and net profit ₹-67 Cr — revenue -22.7% YoY. For annual financials, live price and key ratios, visit DCAL share price screener.
DCAL Quarterly Results — Revenue, Profit & EPS Highlights
Dishman Carbogen Amcis latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore DCAL share price data to track price trends across different timeframes.
- Revenue of ₹511 Cr in Sept 2026 (-41.1% vs Mar 2026, -22.7% vs Sept 2025)
- Net Profit of ₹-67 Cr in Sept 2026 (-404.5% vs Mar 2026, -203.1% vs Sept 2025)
- EBITDA of ₹50 Cr in Sept 2026 (-71.9% vs Mar 2026)
- Operating Margin of 9.0% in Sept 2026 (-10.0pp vs Mar 2026)
- Earnings Per Share of ₹-4.26 in Sept 2026 (-406.5% vs Mar 2026)
Dishman Carbogen Amcis Quarterly Results — Revenue, EBITDA, Net Profit & EPS
DCAL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 511 | 868 | 696 | 661 | 724 | -41.1% | -22.7% |
| Net Profit (₹ Cr) | -67 | 22 | -58 | 65 | 43 | - | - |
| EBITDA (₹ Cr) | 50 | 178 | 77 | 157 | 149 | - | - |
| EPS (₹) | -4.26 | 1.39 | -3.69 | 4.16 | 2.75 | - | - |
| Operating Margin (%) | 9.0% | 19.0% | 9.0% | 23.0% | 20.0% | - | - |
DCAL Share Price Trend — 1-Year Movement Across Quarterly Results
Dishman Carbogen Amcis 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View DCAL yearly price range for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
DCAL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Dishman Carbogen Amcis latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores